Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2689-2694

  Llevadot, J ^a   Giugliano, R P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Clinical trials results; Fibrinolytic therapy; Lanoteplase

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; ASPARAGINE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; FIBRINOLYTIC AGENT; FIBRONECTIN; GLYCINE; LANOTEPLASE; PLASMINOGEN; RETEPLASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; FIBRINOLYTIC THERAPY; GENE DELETION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

EID: 0033763115     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2689     Document Type: Article

References (25)

1. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
2. Fibrin-selective thrombolytic therapy for acute myocardial infarction
3. The fibrinolytic system and thrombolytic therapy
4. The open-artery theory is alive and well-again
5. Optimizing the medical management of acute coronary syndromes
6. Gruppo Italiano Per Lo Studio Della Streptochinasi Nell Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
7. Global Utilization of Streptokinase. And Tissue Plasminogen Activator For Occluded Coronary Arteries (GUSTO) Investigation: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction
9. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
10. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
11. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits
12. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat
13. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator
14. A double-blind, dose-finding study for the iv. bolus injection of SUN9216 (modified tissue plasminogen activator) in acute myocardial infarction: Clinical late Phase-II study
15. Clinical efficacy of SUN9216 (modified tissue plasminogen activator) as compared to alteplase in patients with acute myocardial infarction: A multicenter randomized double-blind comparative study
16. (For The Intime Investigators): Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction
17. Long-term Comparison of Lanoteplase and Alteplase in ST Elevation Myocardial Infarction: 6 Month Follow-up in the InTIME-II Trial
18. Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase
19. An experimental mental model of intracranial hemorrhage during thrombolytic therapy with t-PA
20. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial
21. Lower Dose Heparin with Fibrinolysis is Associated with Lower Rates of Intracranial Hemorrhage
22. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico
23. Assessment of the Safety and Efficacy of a New Throbolytic (ASSENT-2) Investigators: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial